PKC inhibition results in a Kv1.5 + Kvβ1.3 pharmacology closer to Kv1.5 channels

@article{Macias2014PKCIR,
  title={PKC inhibition results in a Kv1.5 + Kv$\beta$1.3 pharmacology closer to Kv1.5 channels},
  author={Alvaro Macias and Alicia de la Cruz and {\'A}ngela Prieto and Diego A. Peraza and Michael M. Tamkun and Teresa Gonzalez and Carmen Valenzuela},
  journal={British Journal of Pharmacology},
  year={2014},
  volume={171}
}
The Kvβ1.3 subunit modifies the gating and pharmacology of Kv1.5 channels in a PKC‐dependent manner, decreasing channel sensitivity to bupivacaine‐ and quinidine‐mediated blockade. Cardiac Kv1.5 channels associate with receptor for activated C kinase 1 (RACK1), the Kvβ1.3 subunit and different PKC isoforms, resulting in the formation of a functional channelosome. The aim of the present study was to investigate the effects of PKC inhibition on bupivacaine and quinidine block of Kv1.5 + Kvβ1.3… Expand
KV1.5–KVβ1.3 Recycling Is PKC-Dependent
TLDR
The results suggest that the trafficking regulation of KV1.5–KVβ1.3 channels is dependent on phosphorylation by PKC and, therefore, they could represent a clinically relevant issue, mainly in those diseases that exhibit modifications in PKC activity. Expand
Regulación de canales Kv4 por subunidades beta accesorias
TLDR
The results demonstrate that calphostin C-mediated abolishment of fast inactivation is not due to the dissociation of KV1.5 and KVβ1.3 and may form functional heterotetrameric channels increasing the channel diversity in vascular smooth muscles. Expand
AMP‐activated protein kinase inhibits Kv1.5 channel currents in pulmonary arterial smooth muscle and HEK 293 cells
Progression of hypoxic pulmonary hypertension is thought to be due, in part, to suppression of voltage-gated potassium channels (Kv) in pulmonary arterial smooth muscle cells that is mediated by theExpand
AMP‐activated protein kinase inhibits Kv1.5 channel currents of pulmonary arterial myocytes in response to hypoxia and inhibition of mitochondrial oxidative phosphorylation
TLDR
Results suggest that AMPK is the primary mediator of reductions in Kv1.5 channels following inhibition of mitochondrial oxidative phosphorylation during hypoxia and by mitochondrial poisons. Expand
Targeting cardiac potassium channels for state-of-the-art drug discovery
  • K. Walsh
  • Medicine
  • Expert opinion on drug discovery
  • 2015
TLDR
Cardiac K+ channels will continue to represent significant clinical targets for drug discovery and innovations in the areas of microfluidics, micropatterning and biosensor fabrication will allow further growth of technologies using primary and stem cell-derived cardiomyocytes. Expand

References

SHOWING 1-10 OF 48 REFERENCES
Kvβ1.3 Reduces the Degree of Stereoselective Bupivacaine Block of Kv1.5 Channels
TLDR
The findings support an overlapping binding site for drugs and Kvβ1.3, which modifies the gating and the pharmacology of Kv1.5 channels, decreasing their sensitivity to block induced by drugs, and competes with them for a binding site at Kv2.3. Expand
Assembly with the Kvbeta1.3 subunit modulates drug block of hKv1.5 channels.
TLDR
The results suggest that the Kvbeta1.3 subunit does not modify the affinity of the charged bupivacaine for its external receptor site but markedly reduces the affinity and quinidine for their internal receptor site in hKv1.5 channels. Expand
Kv1.5-Kvβ Interactions: Molecular Determinants and Pharmacological Consequences
Kv1.5 channels are homotetramers of α-pore subunits mainly present in human atrium and pulmonary vasculature. Thus, Kv1.5 is a pharmacological target for cardiovascular diseases. Kvβ1.3 assembliesExpand
Protein Kinase C (PKC) Activity Regulates Functional Effects of Kvβ1.3 Subunit on KV1.5 Channels
TLDR
The results demonstrate that calphostin C-mediated abolishment of fast inactivation is not due to the dissociation of Kv1.5 and Kvβ1.3 and that PKC inhibition causes a dramatic positive shift of the inactivation curve. Expand
Modulation of the Human Kv1.5 Channel by Protein Kinase C Activation: Role of the Kvβ1.2 Subunit
TLDR
Results demonstrate that coexpression of Kvβ1.2 enhances the response of K v1.5 to PKC activation and that direct phosphorylation of K+ channel subunits is a potential molecular basis for the effect, and suggest that Kv β1. Expand
Kv1.5-Kv beta interactions: molecular determinants and pharmacological consequences.
Kv1.5 channels are homotetramers of alpha-pore subunits mainly present in human atrium and pulmonary vasculature. Thus, Kv1.5 is a pharmacological target for cardiovascular diseases. Kv beta 1.3Expand
Protein Kinase A Phosphorylation Alters Kvβ1.3 Subunit-mediated Inactivation of the Kv1.5 Potassium Channel*
TLDR
Results indicate that Kvβ1.3-induced inactivation is reduced by PKA activation, and that phosphorylation of serine 24 in the subunit NH2 terminus is responsible. Expand
Phosphorylation Is Required for Alteration of Kv1.5 K+ Channel Function by the Kvβ1.3 Subunit*
TLDR
The Kv1.5 K+ channel is functionally altered by coassembly with the Kvβ1.3 subunit, which induces fast inactivation and a hyperpolarizing shift in the activation curve, and kinase regulation after coexpression in human embryonic kidney 293 cells suggests that in activation and voltage sensitivity require phosphorylation by protein kinase C or a related kinase. Expand
Distinct domains of the voltage-gated K+ channel Kvβ1.3 β-subunit affect voltage-dependent gating.
TLDR
The data suggest that Kv β1.3-mediated effects involve at least two distinct domains of this β-subunit, inactivation involves open channel block that is allosterically linked to the external pore, and the Kvβ1. Expand
Structural Basis for Competition between Drug Binding and Kvβ1.3 Accessory Subunit-Induced N-Type Inactivation of Kv1.5 Channels
TLDR
None of the Ala mutations prevented the Kvβ1.3-induced negative shifts in the voltage dependence of activation or slow C-type inactivation, suggesting that these gating effects are mediated by an interaction other than the one for N- type inactivation. Expand
...
1
2
3
4
5
...